Clinical trials
Metastatic Colorectal Adenocarcinoma clinical trials
Below are recruiting metastatic colorectal adenocarcinoma clinical trials, each written for real people, not researchers. We’re tracking 205 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06202001RecruitingPhase 1/Phase 2
Three-drug combo for metastatic colorectal cancer as second treatment
This trial tests a combination of three drugs (irinotecan, TAS-102, and bevacizumab) for people with metastatic colorectal cancer that has already been treated with oxaliplatin-based chemotherapy. The goal is to see if this three-drug combination works better as a second treatment option.
BeijingAges 18–70 - NCT06485713RecruitingPhase 2
Third-line therapy for advanced colorectal cancer
This trial tests a combination of two oral cancer drugs, trifluridine/tipiracil and fufuquitinib, as a third-line treatment for people with advanced colorectal cancer. It may be an option if prior treatments have stopped working.
Wenzhou, ZhejiangAges 18–75 - NCT06922383RecruitingPhase 1/Phase 2
Study of arfolitixorin in advanced colorectal cancer
This study tests a new drug called arfolitixorin given with standard chemotherapy (FOLFOX or FOLFIRI) plus a targeted therapy for people with advanced colorectal cancer that has spread. It may help the chemotherapy work better.
BerlinAges 18 years+ - NCT06943820RecruitingPhase 1/Phase 2
AK129 combination therapy for advanced solid tumors
This trial tests a new combination of drugs (including AK129) for people with advanced solid tumors, specifically lung cancer, head and neck cancer, or colorectal cancer. It is for those who have already tried a platinum chemo and a PD-1/PD-L1 drug but their cancer got worse.
Shenyang, LiaoningAges 18–75 - NCT06978400RecruitingPhase 2
Targeted therapy plus chemo for BRAF mutant colorectal cancer
This trial tests a combination of targeted therapy (dabrafenib) and two other drugs (cetuximab or panitumumab) plus standard chemotherapy (FOLFOX) as a first treatment for people with a specific type of metastatic colorectal cancer that has a BRAF V600E mutation and is microsatellite stable.
MoscowAges 18 years+ - NCT07094204RecruitingPhase 1
A study of ASP5834 for adults with solid tumors and KRAS mutations
This trial is testing a new drug called ASP5834 for people with advanced solid tumors that have a specific change in the KRAS gene. The study will find the best dose and see if it helps shrink tumors.
Santa Monica, CaliforniaAges 18 years+ - NCT06540326RecruitingPhase 2
Second-line therapy for advanced colorectal cancer
This trial tests a combination of chemotherapy with either bevacizumab or cetuximab as a second-line treatment for advanced colorectal cancer. It aims to find which option works better for patients whose first treatment failed.
Hangzhou, ZhejiangAges 18–75 - NCT06018714RecruitingPhase 2
Modified fruquintinib for colorectal cancer with liver metastases
This trial tests a modified version of the drug fruquintinib for people with colorectal cancer that has spread to the liver. It is for those who have had successful liver-directed treatment (surgery, ablation, or radiation) and have no signs of cancer left, then finished chemotherapy without the cancer growing back.
Guangzhou, GuangdongAges 18–75 - NCT01365169Recruiting
How activity level and daily function relate to cancer survival
This study looks at how physical activity (movement during the day) and a clinician-rated “day-to-day function” score relate to overall survival in people with certain cancers. It may help doctors understand who benefits most from activity-focused care and better monitoring.
Houston, TexasAges 18 years+ - NCT07349537RecruitingPhase 1
Study of RMC-5127 for advanced KRAS G12V-mutant solid tumors
This trial tests a new drug called RMC-5127 for people with advanced solid tumors that have a specific KRAS G12V mutation. The study aims to see if this targeted therapy can help when other treatments have stopped working or caused side effects.
New Haven, ConnecticutAges 18 years+ - NCT04854213Recruiting
Study checks radiation effects in colon cancer lung-limited spread
This trial studies how targeted radiation (SBRT) affects cancer biology and immune cells in people with colon cancer that has spread only to a small number of lung nodules. Your tumor tissue will be analyzed to see what changes after treatment.
Naples, NAPOLIAges 18–80 - NCT06484153RecruitingPhase 2
New drug combo for advanced colorectal cancer
This trial tests a new combination of three drugs—fruquintinib (a targeted therapy), pirfenidone (an anti-fibrotic drug), and an immunotherapy (anti-PD-1)—for people with advanced colorectal cancer that has not responded to at least two prior treatments. The goal is to see if this triple therapy can shrink tumors more effectively than current options.
Wuhan, HubeiAges 18–75 - NCT07341737RecruitingPhase 1/Phase 2
SL-28 for advanced solid tumors that haven’t responded to treatment
This trial tests a new drug, SL-28, for people with advanced solid tumors that haven’t responded to or cannot be treated with standard therapies. It aims to find a safe dose and see if the drug can help shrink or slow the growth of your cancer.
Adelaide, South AustraliaAges 18 years+ - NCT06555133RecruitingPhase 2
Study of Y-90, capecitabine, and atezolizumab for advanced colorectal cancer
This trial tests a combination of targeted radiation (Y-90), chemotherapy (capecitabine), and immunotherapy (atezolizumab) for people with colorectal cancer that has spread mainly to the liver and is no longer responding to at least two prior treatments. The goal is to see if this combination can shrink tumors or slow the disease.
Providence, Rhode IslandAges 18 years+ - NCT05727163RecruitingPhase 2
Liver-directed chemotherapy versus standard chemotherapy for RAS-mutated CRC
This Phase 2 study tests whether delivering chemotherapy directly into the liver (with an IV medicine added, depending on the group) works better than standard chemotherapy given through a vein. It is for people whose colorectal cancer has spread to the liver but can’t be removed by surgery yet.
Guangzhou, GuangdongAges 18–75 - NCT07012954RecruitingPhase 1/Phase 2
ctDNA-guided treatment for RAS/BRAF wild-type colorectal cancer
This trial tests a combination of two drugs—cetuximab or bevacizumab plus a chemotherapy pill (trifluridine/tipiracil)—for people with metastatic colorectal cancer that has no RAS or BRAF mutations. It's for patients whose cancer grew after first responding to cetuximab, and who have had other treatments since then.
Guangzhou, GuangdongAges 18–75 - NCT04622423Recruiting
Advanced therapies for colon or pancreas liver metastases
This study tests advanced treatments for cancer that has spread to the liver, either from colon cancer or pancreatic cancer. It may help by targeting liver tumors using treatment plans and, for some participants, liver tissue samples.
Milan, MilanAges 18 years+ - NCT06456515Recruiting
Regorafenib, sintilimab, and electroacupuncture for advanced colorectal cancer
This trial tests a combination of two drugs (regorafenib and sintilimab) plus electroacupuncture for people with advanced colorectal cancer that hasn't responded to standard treatments. The goal is to see if this triple therapy can help shrink tumors or slow the cancer's growth.
ChangzhouAges 18–75 - NCT07201519RecruitingPhase 2
Chemo infusion for liver cancer using a hybrid care model
This trial tests a special type of chemotherapy (hepatic artery infusion) for people with cancers that have spread to the liver, such as colorectal cancer or bile duct cancer (intrahepatic cholangiocarcinoma). It studies whether delivering this treatment partly at a community center and partly at a university hospital is safe and feasible.
Lexington, KentuckyAges 18–99 - NCT06218914RecruitingPhase 1
Study of a new treatment for KRAS G12D cancers
This trial tests a new type of cell therapy (called TCR-T) that targets a specific genetic change (KRAS G12D) in advanced solid tumors that have stopped responding to standard treatments. It may be an option if your cancer has this mutation and you have a specific tissue type (HLA).
Duarte, CaliforniaAges 18 years+ - NCT07542262Enrolling by invitationPhase 2
Low-dose immunotherapy for advanced colorectal and stomach cancer
This study tests a lower dose of immunotherapy in patients with colorectal or stomach cancer that has spread or cannot be removed by surgery. The cancer must have a specific genetic feature (MSI/dMMR). The goal is to see if this approach works well with fewer side effects.
MoscowAges 18 years+ - NCT04895709RecruitingPhase 1/Phase 2
Testing a new cancer drug for advanced solid tumors
This early-phase trial tests how well a new drug (BMS-986340) works alone and combined with other treatments in people with advanced solid tumors that have progressed despite standard care. It also studies tumor samples to look for biomarkers that may predict who benefits.
Clovis, CaliforniaAges 18 years+ - NCT07630961RecruitingPhase 1
New PET Imaging Scans for Advanced Solid Tumors
This trial tests two new radioactive imaging scans (called PET scans) designed to better detect certain advanced cancers like pancreatic, lung, breast, colon, or soft-tissue tumors. The goal is to see if these scans help doctors find and track cancer more accurately than standard imaging.
Chuo Ku, TokyoAges 18 years+ - NCT06329973RecruitingPhase 1/Phase 2
Fruquintinib, sintilimab, and chemo for stomach cancer
This trial tests a combination of three drugs (fruquintinib, sintilimab, and CAPEOX chemotherapy) as a first treatment for advanced stomach or gastroesophageal cancer. The goal is to see if this combination helps slow or shrink the tumor.
Zhengzhou, HenanAges 18–75
Hear when a new Metastatic Colorectal Adenocarcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for metastatic colorectal adenocarcinoma?
- Yes. Clin2 currently lists 205 recruiting metastatic colorectal adenocarcinoma studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a metastatic colorectal adenocarcinoma trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a metastatic colorectal adenocarcinoma trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.